Application of preformed hammerhead ribozymes in the gene therapy of cancer (Review)

International Journal of Molecular Medicine

Volumn 3, Issue 4, 1999, Pages 381-384

  Sioud, Mouldy ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiogenesis; Antisense; Gene therapy; Gliomas; Ribozyme

Indexed keywords

DRUG CARRIER; RIBOZYME;

ANIMAL; DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; METHODOLOGY; NEOPLASM; REVIEW;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; NEOPLASMS; RNA, CATALYTIC;

EID: 0033111032     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.3.4.381     Document Type: Article

References (37)

1. Ulhenbeck OC: A small catalytic oligoribonucleotide. Nature 328: 596-619, 1987.
2. Haseloff J and Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334: 585-591, 1988.
3. Cameron F and Jennings P: Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA 86: 9139-9143, 1989.
4. Cotten M and Birnstiel ML: Ribozyme mediated destruction of RNA in vivo. EMBO J 8: 3861-3866, 1989.
5. Sarver N, Cantin EM, Chang PS, Zia JA, Ladne PA, Stephens DA and Rossi JJ: Ribozymes as potential anti HIV-1 therapeutic agents. Science 247: 1222-1225, 1990.
6. Sioud M and Drlica K: Prevention of HIV-1 integrase expression in E. coli by a ribozyme. Proc Natl Acad Sci USA 88: 7303-7307, 1991.
7. L'Huillier PJ, Davis SR and Bellamy AR: Cytoplasmic delivery of ribozymes leads to efficient reduction in α-lactalbumin mRNA levels in C127I mouse cells. EMBO J 11: 4411-4418, 1992.
8. Funato T, Shitara T, Tone T, Jiao L, Kashani-Sabet M and Scanlon KJ: Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem Pharmacol 48: 1471-1475, 1994.
9. Birikh KR, Heaton PA and Eckstein F: The hammerhead ribozyme - Structure, function and application. Eur J Biochem 245: 1-16, 1997.
10. Feng H, Jackson WH, Goldman CK Jr, Rancourt C, Wang M, Dusing SK, Siegal G, Curiel DT: Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 15: 866-870, 1997.
11. Sioud M, Natvig JB and Førre Ø: Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J Mol Biol 223: 7303-7307, 1992.
12. Sioud M: Interaction between tumor necrosis factor α ribozyme and cellular proteins. J Mol Biol 242: 619-629, 1994.
13. Sioud M: Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-α production by peritoneal cells in vitro and in vivo. Eur J Immunol 26: 1026-1031, 1996.
14. Sioud M, Opstad A, Zhao JQ, Levitz R, Benham C and Drlica K: In vivo decay kinetic parameters of hammerhead ribozymes. Nucleic Acids Res 22: 5571-5575, 1994.
15. McCall MJ, Hendry P and Jennings PA: Minimal sequence requirements for ribozyme activity. Proc Natl Acad Sci USA 89: 5710-5714, 1992.
16. Taylor NR, Kaplan BE, Swiderski P, Li H and Rossi JJ: Chemeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res 20: 4559-4565, 1992.
17. Sioud M, Opstad A, Hendry P, Lockett TJ, Jennings PA and McCall MJ: A minimised hammerhead ribozyme with activity against interleukin-2 in human cells. Biochem Biophys Res Commun 231: 397-402, 1997.
18. Heidenreich O, Pieken W and Eckstein F: Chemically modified RNA. FASEB J 7: 90-96, 1993.
19. Pieken WA, Olsen DB, Benseler F, Aurup H and Eckstein F: Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253: 314-317, 1991.
20. Heidenreich O and Eckstein F: Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J Biol Chem 267: 1904-1909, 1992.
21. Yang J, Perrealt JP, Labuda D, Usman N and Cedergren R: Mixed DNA/RNA polymers are cleaved by the hammerhead ribozyme. Biochemistry 29: 11156-11160, 1990.
22. Olsen DB, Benseler F, Aurup H, Pieken WA and Eckstein F: Study of a hammerhead ribozyme containing 2′-modified adenosine residues. Biochemistry 30: 9735-9741, 1991.
23. Heidenreich O, Benseler F, Fahrenholz A and Eckstein F: High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J Biol Chem 269: 2131-2138, 1994.
24. Beigelman L, McSwiggen JA, Draper KG, Gonzalez C, Jensen K, Karpesky AM, Sweedler D, Tracz D, Grimm S, Wincott FE, Thackray VG and Usman N: Chemical modification of hammerhead ribozymes. J Biol Chem 270: 25702-25708, 1995.
25. Jarvis TC, Wincott FE, Alby LJ, McSwiggen JA, Beigelman L, Gustofson J, DiRenzo A, Levy K, Arthur M, Matulic-Adamic J, Karpeisky A, Gonzalez C, Woolf TM, Usman N and Stinchcomb DT: Optimizing the cell efficacy of synthetic ribozymes. J Biol Chem 271: 29107-29112, 1996.
26. Sioud M and Sørensen R: A nuclease-resistant protein kinase Cα ribozyme blocks glioma cell growth. Nat Biotech 16: 556-561, 1998.
27. Metcaf D: The Hemopoietic Colony-Stimulating Factors. Elsevier, Amsterdam, 1984.
28. Iversen PO and Sioud M: Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells. Blood 92: 4263-4268, 1998.
29. Lange W, Cantin EM, Finke J and Dolken G: In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7: 1786-1794, 1993.
30. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614-620, 1997.
31. Black PM: Brain tumors. Part I. N Engl J Med 324: 1471-1476, 1991.
32. Leirdal M and Sioud M: Ribozyme inhibition of the protein kinase Ca triggers apoptosis in glioma cells. Br J Cancer (In press).
33. Lyngstadaas SP, Risnes S, Sproat BS, Thrane PS and Prydz HP: A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse amel in vivo. EMBO J 14: 5224-5229, 1995.
34. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
35. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
36. Leirdal M and Sioud M: High cleavage activity and stability of hammerhead ribozymes with a uniform 2′-amino pyrimidine modification. Biochem Biophys Res Commun 250: 171-174, 1998.
37. Bramlage B, Luzi E and Eckstein F: Designing ribozymes for the inhibition of gene expression. TibTech 16: 434-438, 1998.